SRNE - Sorrento anti-SARS-CoV-2 antibodies show encouraging action in preclinical studies

Sorrento Therapeutics (SRNE) shares up 6% in premarket, in reaction to preclinical data on COVI-GUARD (STI-1499) and COVI-AMG (STI-2020) antibodies against SARS-CoV-2, and both demonstrated neutralizing activities against SARS-CoV-2 virus infection.In May, it announced that STI-1499 completely inhibited SARS-CoV-2 infection in an in vitro experiment at low concentrationSTI-2020 is an affinity-matured version of the COVI-GUARD and demonstrated a greater than 50-fold increase in potency in in vitro studies.Animal models treated with a single dose of 500 µg STI-2020 started gaining weight within 48 hours of administration, as compared to control animals that steadily lost weight for 5 days before recovery. At day 5, all five STI-2020-treated animals had undetectable viral load in the lungs.The company says, "STI-2020 has the potential to be utilized for both early and late therapeutic interventions, as well as for prophylaxis, with the potential of having a low efficacious dose.”The FDA has signed off on a Phase 1 study of STI-1499 in hospitalized

For further details see:

Sorrento anti-SARS-CoV-2 antibodies show encouraging action in preclinical studies